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A report on the European Molecular Biology Laboratory
(EMBL) ‘Oncogenes and Growth Control’ meeting,
Heidelberg, Germany, 17-20 April 2004.
The four-day meeting at the European Molecular Biology
Laboratory (EMBL) brought together many of the specialists,
mainly from Europe and the USA, working on cancer and
signal transduction. It was the 20th meeting in this series,
and celebrated 50 years since the discovery of protein kinases
by Burnett and Kennedy (J Biol Chem 1954, 211:969-980)
and 25 years since the discovery of tyrosine phosphorylation
by Hunter and colleagues (Eckhart et al., Cell 1979, 18:925-
933). Much of the meeting focused on advances obtained
using murine models of oncogenesis, and this aspect was
nicely complemented by more mechanistic talks.
Oncogenic signaling
One of the most important recent advances in the field of
kinase research was the characterization by Tony Hunter
(Salk Institute for Biological Sciences, La Jolla, USA) and his
colleagues of the evolutionary relationships between the 518
mammalian protein kinases encoded in the human genome.
The kinases represent the largest family of human enzymes,
collectively termed the kinome, and knowledge about their
evolution has greatly facilitated research into these impor-
tant enzymes. The value of the kinome data was exemplified
by the many talks throughout the meeting describing work
in which information from Hunter’s study was used. In his
talk, Hunter described the families of human kinases and the
domains that they contain. Interestingly, 40% of all kinases
have multiple splice variants and 10% of the total encode
catalytically deficient enzymes that have been termed
pseudokinases. The roles of these inactive enzymes are
poorly defined, but recent examples indicate that a number
of pseudokinases, such as ErbB3 and STRAD, play roles in
activating conventional protein kinases, namely the epider-
mal growth factor (EGF) receptor and the serine-threonine
kinase LKB1, respectively. 
Julian Downward (Cancer Research UK, London, UK), made
use of Hunter’s kinome database in an RNA interference
(RNAi) screen of all human kinases, to search for enzymes
that regulate senescence induced by Ras. One of the novel
targets identified encodes MINK, a kinase that resembles the
yeast Ste20 kinase; MINK was shown to be stimulated by Ras
through the extracellular signal-regulated kinase (ERK) or
mitogen-activated protein (MAP) kinase pathway. Activation
of MINK by Ras leads to the activation of p38 MAP kinase
through the upstream TAK/MKK6 signaling pathway, and
activation of p38 was shown to be required for the senescence
pathway. This pathway represents one of the longest and
most complicated kinase cascades described to date, involv-
ing at least eight or nine different protein kinases.
Increasing numbers of protein-kinase inhibitors are being
developed and employed to define the physiological roles of
the kinases. But a major concern relating to the interpreta-
tion of these studies is the fact that most of the drugs that
have been developed thus far target the ATP-binding pocket
of kinases and are therefore unlikely to be completely spe-
cific, as this site is relatively conserved between different
kinases. Giulio Superti-Furga (Cellzome Inc. and EMBL,
Heidelberg, Germany) presented an elegant approach to
identifying other kinases that might be targeted by a kinase
inhibitor; in this approach, the inhibitor is immobilized onto
an insoluble resin and used to affinity-purify from cell
extracts protein kinases that bind the drug. The enzymes
that have bound to the drug are then detected by mass spec-
trometry. Using Gleevec/STI-571 as an example, Superti-
Furga and colleagues purified a kinase involved in
Alzheimer’s disease, which was not previously known to betargeted by this drug. Superti-Furga speculated that Gleevec
might therefore potentially be used to treat Alzheimer’s
disease. Thus, his approach to identifying targets of kinase
inhibitors may not only lead to knowledge concerning the
overall specificity of inhibitors, but, when used with clini-
cally approved drugs, could potentially lead to the develop-
ment of new therapeutic uses for these compounds.
A couple of years ago much excitement was caused by the
finding that most melanomas are caused by mutations in the
B-Raf kinase that result in activation of the ERK pathway.
Remarkably, both activating and inactivating mutations in
B-Raf were found in melanomas as well as in other cancers.
David Barford (Institute of Cancer Research, London, UK)
described studies that he has done with Richard Marais (also
at the Institute of Cancer Research) to elucidate the three-
dimensional structure of the catalytic domain of B-Raf. The
results of this work demonstrate the structural basis by
which cancer-associated mutations regulate B-Raf activity.
Most interestingly, although most mutations lead to a higher
B-Raf activity, a subset of mutants found in human cancers
actually inactivate B-Raf; the structural analysis revealed
that although these mutations abolish B-Raf activity, they
stabilize B-Raf in a conformation similar to that of the active
enzyme. How these mutant forms of B-Raf then go on to
activate ERK is not known, but one possibility is that the
active conformation of B-Raf can stimulate the activation of
c-Raf, by an as yet unidentified mechanism.
Signaling, growth and polarity
An interesting feature of the meeting was the use of spectac-
ular movies of live cells, which kept the audience interested
and explained the physiological processes better than words
or fixed images could ever do. Seeing is definitely believing!
This was exemplified in the talk by Jürgen Knoblich
(Research Institute of Molecular Pathology, Vienna, Austria)
who established that the Aurora kinase forms a complex
with a novel protein named Bora that it phosphorylates. This
phosphorylation event was shown to play an important role
in enabling proteins, such as the cell-fate determinant
Numb, to be asymmetrically segregated into specific daugh-
ter cells after cell division. Knoblich proposed that asymmet-
ric localization of Numb requires both a temporal signal
mediated by the activation of Aurora by the Cdc2 cell-cycle-
regulatory kinase as well as a spatial signal provided by a
complex made up of the spatially localized Par3 and Par6
proteins with atypical protein kinase C (PKC). 
Many talks discussed the roles of the signal transducer
β-catenin/Armadillo in the regulation of transcriptional
responses in various organisms. The β-catenin protein is
known to play a critical role in the canonical Wnt signaling
pathway, where it lies between the cell-surface Wnt signal
receptor and the nuclear transcription factor LEF1.
Boudewijn Burgering (University Medical Center, Utrecht,
The Netherlands) described the discovery of the forkhead
transcription factor Foxo as a novel binding partner of
β-catenin, and provided biochemical and genetic evidence that
β-catenin enhances transcriptional responses mediated by the
Foxo transcription factors in response to oxidative stress.
In the past few years there has been a great deal of research
into understanding the roles of the serine-threonine kinase
LKB1, which is mutated in the rare inherited Peutz-Jeghers
cancer syndrome. Hans Clevers (University Medical Center,
Utrecht, The Netherlands) displayed striking movies and
images showing that the activation of LKB1 in unpolarized
intestinal cell lines induces the complete polarization of these
cells. The changes included the formation of microvilli at the
apical edge, cytoskeletal rearrangements that are characteris-
tic of polarized colonic cells, and the formation of gap junc-
tions. It was previously thought that these events required
cell-cell contacts, but this may not be the case, as LKB1 acti-
vation induced cell polarization even in isolated cells. It will
be interesting to establish the downstream signaling pathway
by which LKB1 regulates these cellular events and whether it
involves the recently identified LKB1 substrates belonging to
the AMP-activated protein kinase (AMPK) family. Tomi
Mäkelä (University of Helsinki, Finland) demonstrated that
colon cancer cells from patients with mutations in LKB1 had
elevated levels of cyclooxygenase-2 (COX-2) activity. Employ-
ing the COX-2 inhibitor celecoxib, he demonstrated a
remarkable decrease in the size of hamartoma tumors in the
intestine of LKB1-/+ heterozygous mice as well as in several
human patients with Peutz-Jeghers syndrome. This work
indicates that celecoxib may be useful for the treatment of
cancers that have mutations in LKB1.
A major hope is that knowledge gained from understanding
the role of signaling pathways in regulating cell growth and
proliferation can be exploited to develop more effective anti-
cancer therapies. Scott Lowe (Cold Spring Harbor Laboratory,
USA) described work showing that cancers in mice caused by
the activation of protein kinase B (PKB; also known as Akt)
were effectively treated by a combination of rapamycin, which
inhibits the molecular target of rapamycin (mTOR), and con-
ventional chemotherapeutic agents. But these potent effects
were not observed in cancers with other genotypes, such as
those caused by the overexpression of the cell-death inhibitor
Bcl-2. Lowe also demonstrated that the eIF4E translation
factor, which is regulated by Akt and mTOR, is highly onco-
genic, and cancers overexpressing this factor failed to
respond to rapamycin. These results provide a clear example
of how critical it will be to understand the genotype of cancer
cells and which signaling pathways are activated in them if we
are to be able to treat these malignancies efficiently.
Invasion and metastasis
Recent work by Richard Treisman (Cancer Research UK,
London, UK) has found that transcription dependent on the
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Genome Biology 2004, 5:332serum response factor (SRF) is regulated by the Rho GTPase
through actin polymerization, but the mechanism by which
this is achieved was not understood. This question now seems
to have been resolved, as Treisman described a novel SRF
binding partner and co-activator named MAL, which is
anchored onto polymerized actin in the cytosol and released
into the nucleus after activation of the Rho GTPase. In this
way, MAL is thought to play a role in SRF-dependent tran-
scription. Interestingly, MAL was also phosphorylated by
ERK, another key regulator of immediate-early gene tran-
scription by SRF. The next advance in this area of work will
be to elucidate the role that the phosphorylation of MAL
plays in the regulation of SRF function. In the subsequent
talk, Pernille Rørth (EMBL, Heidelberg, Germany) showed
that MAL complexed to SRF plays a critical role in border-cell
migration during Drosophila oogenesis. Rørth also proposed
that accumulation of nuclear MAL is induced by cell deforma-
tion during migration, and that invasive cells go through mul-
tiple MAL/SRF activation cycles as they migrate.
Another GTPase that received attention at the meeting was
Ral. Chris Marshall (Institute of Cancer Research, London,
UK) has studied the function of Ral-GDS, a Ras-dependent
activator of Ral, using knockout techniques, and he
described work that demonstrates that the Ral pathway is
not oncogenic alone but cooperates with Ras or Raf to
induce cellular transformation. Moreover, he described the
discovery of a novel Ral effector protein named ZONAB,
which, like β-catenin, has functions in the nucleus regulating
transcription and at the plasma membrane controlling cell-
cell contacts. Overall, the meeting demonstrated the wealth
of research into important signaling pathways that regulate
cell growth and cancer. We can look forward to further excit-
ing advances in the field over the coming months. 
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